{"filing":{"accession_number":"0001493152-26-047711","cik":"0002030763","ticker":"WGRX","company_name":"DataMeds AI, Inc.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-19","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2030763/000149315226047711/form8-k.htm"},"events":[{"id":36330,"run_id":33493,"accession_number":"0001493152-26-047711","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.94,"summary":"DataMeds AI announced on October 20, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving a delisting notice on April 13, 2026 for failure to maintain the required minimum stockholders' equity of $2.5 million. The company has remediated the deficiency as of October 19, 2026, but faces continued delisting risk if it fails to evidence compliance upon filing its next periodic report.","company_name":"DataMeds AI, Inc.","ticker":"WGRX","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40715,"accession_number":"0001493152-26-047711","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"DataMeds AI announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving a delisting notice on April 13, 2026 for failure to maintain minimum stockholders' equity of $2.5 million. The press release explicitly states the company originally faced delisting proceedings and that \"if the Company fails to evidence compliance upon filing its next periodic report it may be subject to delisting.\" This disclosure directly addresses delisting risk and the company's remediation of a prior delisting threat.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T13:25:40.454475+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40716,"accession_number":"0001493152-26-047711","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that DataMeds AI received a deficiency letter on April 13, 2026 for failing to meet Nasdaq's minimum $2.5 million stockholders' equity requirement, and has now regained compliance as of October 19, 2026. While the company has resolved the immediate delisting risk, the disclosure centers on the company's prior non-compliance with continued listing standards and the path to regaining compliance—the core substance of delisting-risk disclosure. The press release explicitly references the original \"notice of delisting\" and the company's need to maintain compliance going forward, noting that failure to evidence compliance upon the next periodic report may result in delisting.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T13:25:40.454475+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40715,"accession_number":"0001493152-26-047711","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"DataMeds AI announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving a delisting notice on April 13, 2026 for failure to maintain minimum stockholders' equity of $2.5 million. The press release explicitly states the company originally faced delisting proceedings and that \"if the Company fails to evidence compliance upon filing its next periodic report it may be subject to delisting.\" This disclosure directly addresses delisting risk and the company's remediation of a prior delisting threat.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T13:25:40.454475+00:00","company_name":"DataMeds AI, Inc.","ticker":"WGRX","filing_date":"2026-10-20"},{"id":40716,"accession_number":"0001493152-26-047711","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that DataMeds AI received a deficiency letter on April 13, 2026 for failing to meet Nasdaq's minimum $2.5 million stockholders' equity requirement, and has now regained compliance as of October 19, 2026. While the company has resolved the immediate delisting risk, the disclosure centers on the company's prior non-compliance with continued listing standards and the path to regaining compliance—the core substance of delisting-risk disclosure. The press release explicitly references the original \"notice of delisting\" and the company's need to maintain compliance going forward, noting that failure to evidence compliance upon the next periodic report may result in delisting.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T13:25:40.454475+00:00","company_name":"DataMeds AI, Inc.","ticker":"WGRX","filing_date":"2026-10-20"}]}